Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become

Eli Lilly (NYSE: LLY) has seen huge success in the GLP-1 weight-loss drug space with Mounjaro and Zepbound. Although it was second to market after Novo Nordisk (NYSE: NVO) in the GLP-1 space, better patient outcomes and Novo Nordisk's inability to keep up with demand enabled Eli Lilly to take the industry lead. But there's a longer-term problem here, and Eli Lilly is attempting to get ahead of it, even if it means some new drug candidates fall by the wayside. Here's what you need to know.

An Eli Lilly GLP-1 drug flames out

Eli Lilly recently stopped its development of a new GLP-1 weight-loss drug. The company had expectations for the drug's efficacy, and it didn't live up to them. It's unfortunate, but it happens. Investors shouldn't take this one event and blow it out of proportion.

Image source: Getty Images.

Discovering new drugs is an expensive, time-consuming, and difficult process. Pharmaceutical companies like Eli Lilly are always on the lookout for new drug candidates, and a lot of them won't work out as well as hoped. In fact, Eli Lilly's willingness to hold its drug development to high standards is a sign of strength. And this speaks to two important facts.

1. Eli Lilly needs to diversify

In the second quarter of 2026, Mounjaro and Zepbound accounted for nearly 65% of the company's top line. Add in the company's new GLP-1 pill, Foundayo, and the company's reliance on GLP-1 drugs rises to just over 65%. To be fair, these drugs are doing very well, with still-impressive sales growth. And there's a huge opportunity ahead, given the size of the weight-loss market.

But drugs only get patent protection for a limited time. Eli Lilly knows full well that its GLP-1 success will be time-limited. Eventually, generic competition will come in, and its GLP-1 revenues will decline. Which is why it was looking for new drug candidates, including in the GLP-1 space.

2. Eli Lilly is building off its GLP-1 success

What's important to keep in mind is that every drug candidate doesn't turn into a viable drug to sell. That's just how it goes. It is actually more beneficial for investors to look at Eli Lilly's drug development efforts from a broader perspective. When you do that, the picture is much brighter.

Notably, Eli Lilly has been using the cash windfall from its GLP-1 drugs to invest in its drug pipeline. That includes funding in-house research efforts, but it has also allowed the healthcare giant to use acquisitions to expand its drug portfolio into new areas. For example, it recently announced three acquisitions in one day, which collectively catapulted it into the infectious disease space.

This isn't exactly unusual in the drug industry. Small companies with attractive drug candidates are often swallowed up by pharmaceutical giants looking to bolster their drug pipelines. What's worth highlighting is the speed with which Eli Lilly is moving. Since the company announced its move into infectious diseases in May, it has already announced two more acquisitions. This is a company that is moving with purpose.

Not all of these investments will work out

Just like the GLP-1 drug candidate that Eli Lilly dropped, not every acquisition it makes will be a winner. Think of it more like throwing spaghetti at a wall to see what sticks. The bar is high for new drugs, but Eli Lilly knows it has to prepare before its GLP-1 drugs are no longer the profit engine they are today. Moving quickly, including letting weak drugs fall to the wayside, is the right move, and shareholders should be pleased with what they see here.

Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool has a disclosure policy.